View full meeting coverage »

Eyetube Meeting Coverage:

American Academy of Ophthalmology Annual Meeting 2020

 

Replay
Cancel

Your 25-second video preview has ended.

to continue watching, please Log In or Register:


Log in / Register

A Research Analysis of Brolucizumab in the Real World

  Channels: Retina | Posted 11/5/2020

Michael S. Ip, MD, discusses the rate and risk stratification of the safety profile of brolucizumab-dbll (Beovu, Novartis) in the treatment of wet age-related macular degeneration (AMD), with reference to the HAWK and HARRIER phase 3 clinical trials. Dr. Ip talks about the retrospective analysis he and his colleagues conducted of real-world patients who received brolucizumab for the treatment of wet AMD and shares some interesting points from their analysis.

brolucizumab • Clinical Trials • HAWK and HARRIER • retina-meeting-recap • Wet AMD


8 / 25 Series: American Academy of Ophthalmology Annual Meeting 2020


More Videos in this Series


View full meeting coverage (25 videos)
These programs are not affiliated with the official program of AAO 2020.